Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Context Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for hormonally driven and immunologically defined cancers, with a particular emphasis on women’s oncology. The company operates within the biotechnology and oncology drug development industries and is publicly traded on the Nasdaq under the ticker CNTX. Its business model centers on advancing targeted biologics and immuno-oncology programs from early clinical development through proof-of-concept.
The company’s primary value drivers are its internally developed and in-licensed therapeutic candidates targeting tumor-specific antigens, with a strategic shift in recent years toward T-cell–engaging biologics. Context Therapeutics was founded in 2015 and initially focused on progesterone receptor–positive cancers; following mixed clinical outcomes, the company streamlined its portfolio and repositioned its strategy toward differentiated immuno-oncology assets addressing unmet needs in ovarian and other gynecologic cancers.
Business Operations
Context Therapeutics conducts operations as a single reporting segment focused on oncology research and development. The company does not generate product revenue and instead invests in preclinical research, clinical trials, and regulatory activities to advance its pipeline. Its lead program, CNTX-134, is a Claudin 6 (CLDN6)–targeted CD3 bispecific T-cell engager designed to activate the immune system against CLDN6-expressing tumors, particularly in ovarian and endometrial cancers.
Operations are primarily U.S.-based, with research and development activities supported through a combination of internal teams and outsourced contract research organizations. The company controls its core intellectual property through licenses and internal development and has no commercial manufacturing or sales infrastructure. Context Therapeutics maintains collaborations with academic institutions and industry partners to support translational research and early-stage development.
Strategic Position & Investments
Strategically, Context Therapeutics has prioritized building a focused immuno-oncology pipeline aimed at tumor-restricted targets to improve efficacy while limiting off-tumor toxicity. The in-licensing of CNTX-134 represented a pivotal investment, signaling a move away from hormone-only mechanisms toward immune-mediated approaches. The company has publicly stated its intent to allocate capital toward advancing CNTX-134 through clinical development while evaluating additional CLDN6-related or women’s cancer–focused assets.
The company has divested or discontinued earlier hormone receptor programs to conserve capital and sharpen strategic focus. Beyond its lead asset, Context Therapeutics maintains early-stage discovery efforts; however, detailed disclosures on additional named candidates are limited, and data inconclusive based on available public sources regarding the breadth of its preclinical portfolio beyond CLDN6-directed therapies.
Geographic Footprint
Context Therapeutics is headquartered in the United States, with its principal executive offices in Philadelphia, Pennsylvania. Its operational footprint is concentrated in North America, where management, clinical oversight, and corporate functions are based. Clinical trials may include international investigative sites depending on protocol design, but the company does not report material overseas facilities or subsidiaries.
While global in strategic outlook due to the nature of oncology drug development, Context Therapeutics’ international presence is primarily indirect, consisting of collaborations, clinical research sites, and intellectual property rights that may extend into Europe and other regions as clinical programs advance.
Leadership & Governance
Context Therapeutics is led by an executive team with experience in oncology drug development, clinical research, and biotechnology company operations. Leadership emphasizes disciplined capital allocation, scientific rigor, and a targeted development strategy focused on high-unmet-need cancer indications.
Key executives include:
- Martin Lehr, M.D. – President and Chief Executive Officer
- Michelle Keefe – Chief Financial Officer
- Karin Shanahan, M.D. – Chief Medical Officer
The board and management team collectively guide corporate strategy, oversee pipeline prioritization, and ensure governance aligned with public company standards and regulatory requirements.